EE03685B1 - Asendatud benseensulfoonamiidi derivaadid kui COX-2 inhibiitorite eelravimid - Google Patents
Asendatud benseensulfoonamiidi derivaadid kui COX-2 inhibiitorite eelravimidInfo
- Publication number
- EE03685B1 EE03685B1 EE9800351A EE9800351A EE03685B1 EE 03685 B1 EE03685 B1 EE 03685B1 EE 9800351 A EE9800351 A EE 9800351A EE 9800351 A EE9800351 A EE 9800351A EE 03685 B1 EE03685 B1 EE 03685B1
- Authority
- EE
- Estonia
- Prior art keywords
- cox
- prodrugs
- inhibitors
- benzenesulfonamide derivatives
- substituted benzenesulfonamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/58—One oxygen atom, e.g. butenolide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63151496A | 1996-04-12 | 1996-04-12 | |
PCT/US1997/005497 WO1997038986A1 (en) | 1996-04-12 | 1997-04-11 | Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EE9800351A EE9800351A (et) | 1999-04-15 |
EE03685B1 true EE03685B1 (et) | 2002-04-15 |
Family
ID=24531540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EE9800351A EE03685B1 (et) | 1996-04-12 | 1997-04-11 | Asendatud benseensulfoonamiidi derivaadid kui COX-2 inhibiitorite eelravimid |
Country Status (40)
Country | Link |
---|---|
US (4) | US5932598A (xx) |
EP (2) | EP0892791B1 (xx) |
JP (2) | JP3382624B2 (xx) |
KR (1) | KR100387658B1 (xx) |
CN (1) | CN1098256C (xx) |
AP (1) | AP1009A (xx) |
AT (2) | ATE233743T1 (xx) |
AU (1) | AU734275C (xx) |
BG (2) | BG64531B1 (xx) |
BR (2) | BR9708574A (xx) |
CA (1) | CA2249009C (xx) |
CU (1) | CU23116A3 (xx) |
CZ (1) | CZ297430B6 (xx) |
DE (2) | DE69719496T2 (xx) |
DK (2) | DK1288206T3 (xx) |
EA (1) | EA003319B1 (xx) |
EE (1) | EE03685B1 (xx) |
ES (2) | ES2194195T3 (xx) |
GE (1) | GEP20032998B (xx) |
HK (1) | HK1019741A1 (xx) |
HU (1) | HU225473B1 (xx) |
IL (3) | IL125849A (xx) |
IS (2) | IS2156B (xx) |
LT (1) | LT4586B (xx) |
LV (1) | LV12239B (xx) |
ME (1) | ME00768B (xx) |
NO (1) | NO314184B1 (xx) |
NZ (1) | NZ331542A (xx) |
OA (1) | OA11015A (xx) |
PL (1) | PL195955B1 (xx) |
PT (2) | PT1288206E (xx) |
RO (1) | RO121338B1 (xx) |
RS (1) | RS50019B (xx) |
SI (2) | SI9720035B (xx) |
SK (1) | SK285353B6 (xx) |
TR (1) | TR199802049T2 (xx) |
TW (1) | TW585857B (xx) |
UA (1) | UA47475C2 (xx) |
WO (1) | WO1997038986A1 (xx) |
ZA (1) | ZA973146B (xx) |
Families Citing this family (280)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996038418A1 (en) | 1995-06-02 | 1996-12-05 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
US5908858A (en) | 1996-04-05 | 1999-06-01 | Sankyo Company, Limited | 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses |
WO1997038986A1 (en) * | 1996-04-12 | 1997-10-23 | G.D. Searle & Co. | Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors |
US6586458B1 (en) | 1996-08-16 | 2003-07-01 | Pozen Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
US8022095B2 (en) | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
PT971714E (pt) * | 1997-04-03 | 2002-12-31 | Searle & Co | Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia |
US20040072889A1 (en) * | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
RS49982B (sr) | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
US6887893B1 (en) * | 1997-12-24 | 2005-05-03 | Sankyo Company, Limited | Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia |
US6136804A (en) * | 1998-03-13 | 2000-10-24 | Merck & Co., Inc. | Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions |
JP2002506024A (ja) * | 1998-03-13 | 2002-02-26 | メルク エンド カムパニー インコーポレーテッド | 急性冠動脈虚血症候群および関連状態に対する併用療法および組成物 |
JP2002517423A (ja) | 1998-06-08 | 2002-06-18 | アドバンスド メディスン インコーポレーテッド | シクロオキシゲナーゼ−2の多結合インヒビター |
AR024222A1 (es) * | 1998-10-16 | 2002-09-25 | Palau Pharma Sa | Imidazoles con actividad antiinflamatoria un procedimiento para su preparacion y composiciones farmaceuticas que lo contienen |
EP1126841B1 (en) * | 1998-11-02 | 2004-12-15 | Merck & Co., Inc. | Combinations of a 5ht1b/1d agonist and a selective cox-2 inhibitor for the treatment of migraine |
AU1398899A (en) * | 1998-11-12 | 2000-06-05 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with centrally acting analgesics |
US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
US6649645B1 (en) * | 1998-12-23 | 2003-11-18 | Pharmacia Corporation | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia |
US20030119895A1 (en) * | 1998-12-23 | 2003-06-26 | Pharmacia Corporation | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia |
US20030013739A1 (en) * | 1998-12-23 | 2003-01-16 | Pharmacia Corporation | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia |
AU3596500A (en) * | 1999-02-19 | 2000-09-04 | Pozen, Inc. | Formulation of 5-ht agonists with cox-2 inhibitors |
US20010024664A1 (en) * | 1999-03-19 | 2001-09-27 | Obukowicz Mark G. | Selective COX-2 inhibition from edible plant extracts |
WO2001028548A1 (en) * | 1999-10-19 | 2001-04-26 | Texas Heart Institute | Treatment of heart disease with cox-2 inhibitors |
NZ513960A (en) * | 1999-12-08 | 2004-02-27 | Pharmacia Corp | Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
SK9032002A3 (en) * | 1999-12-22 | 2003-03-04 | Pharmacia Corp | Dual-release compositions of a cyclooxygenase-2 inhibitor |
EP1246621A4 (en) * | 1999-12-23 | 2004-11-24 | Nitromed Inc | NITROSED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS FOR THEIR USE |
AU3846801A (en) | 2000-02-16 | 2001-08-27 | Brigham & Womens Hospital | Aspirin-triggered lipid mediators |
WO2001064669A1 (en) | 2000-03-03 | 2001-09-07 | Pfizer Products Inc. | Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
US20070072861A1 (en) * | 2000-03-27 | 2007-03-29 | Barbara Roniker | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders |
AU2001253749A1 (en) * | 2000-04-25 | 2001-11-07 | Pharmacia Corporation | 2-fluorobenzenesulfonyl compounds for the treatment of inflammation |
ES2166710B1 (es) * | 2000-04-25 | 2004-10-16 | J. URIACH & CIA, S.A. | Nuevos compuestos heterociclicos con actividad antiinflamatoria. |
CA2414674A1 (en) * | 2000-07-13 | 2002-01-24 | Pharmacia Corporation | Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders |
ATE366569T1 (de) | 2000-07-20 | 2007-08-15 | Lauras As | Verwendung von cox-2 inhibitoren als immunostimulantien zur behandlung von hiv oder aids |
US20030219461A1 (en) * | 2000-09-12 | 2003-11-27 | Britten Nancy J. | Parenteral combination therapy for infective conditions |
EP1322311A1 (en) * | 2000-09-18 | 2003-07-02 | Merck & Co., Inc. | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist |
AU2002213467A1 (en) * | 2000-10-11 | 2002-04-22 | Chemocentryx, Inc. | Modulation of ccr4 function |
JP2004517838A (ja) * | 2000-12-15 | 2004-06-17 | ファルマシア・コーポレーション | 非食用植物抽出物による選択的cox−2阻害 |
WO2002047706A2 (en) * | 2000-12-15 | 2002-06-20 | Pharmacia Corporation | Selective cox-2 inhibition from plant extracts |
US6706724B2 (en) | 2000-12-21 | 2004-03-16 | Nitromed, Inc. | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
WO2002062391A2 (en) * | 2001-02-02 | 2002-08-15 | Pharmacia Corporation | Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea |
WO2002078625A2 (en) * | 2001-03-28 | 2002-10-10 | Pharmacia Corporation | Therapeutic combinations for cardiovascular and inflammatory indications |
MY137736A (en) * | 2001-04-03 | 2009-03-31 | Pharmacia Corp | Reconstitutable parenteral composition |
ITMI20010733A1 (it) | 2001-04-05 | 2002-10-05 | Recordati Chem Pharm | Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria |
US20030105144A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
US6673818B2 (en) | 2001-04-20 | 2004-01-06 | Pharmacia Corporation | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation |
WO2002094264A1 (en) * | 2001-05-23 | 2002-11-28 | Tularik Inc. | Ccr4 antagonists |
US20030153801A1 (en) * | 2001-05-29 | 2003-08-14 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease |
CA2448627A1 (en) * | 2001-05-31 | 2002-12-05 | Pharmacia Corporation | Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol |
US20060167074A1 (en) * | 2001-06-19 | 2006-07-27 | Norbert Muller | Methods and compositions for the treatment of psychiatric disorders |
DE10129320A1 (de) * | 2001-06-19 | 2003-04-10 | Norbert Mueller | Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen |
UA80682C2 (en) * | 2001-08-06 | 2007-10-25 | Pharmacia Corp | Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition |
US20040067992A1 (en) * | 2001-08-10 | 2004-04-08 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
WO2003013655A2 (en) * | 2001-08-10 | 2003-02-20 | Pharmacia Corporation | Carbonic anhydrase inhibitors |
US20030114416A1 (en) * | 2001-08-14 | 2003-06-19 | Pharmacia Corporation | Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
US20050101563A1 (en) * | 2001-08-14 | 2005-05-12 | Pharmacia Corporation | Method and compositions for the treatment and prevention of pain and inflammation |
AR038957A1 (es) | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
BR0212435A (pt) * | 2001-09-10 | 2004-08-17 | Sugen Inc | Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase |
AU2002330042A1 (en) | 2001-09-18 | 2003-04-01 | Onconova Therapeutics, Inc. | Process for the preparation of 1,5-diarylpyrazoles |
US20030114483A1 (en) * | 2001-09-18 | 2003-06-19 | Pharmacia Corporation | Compositions of chromene cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain |
WO2003024958A2 (en) * | 2001-09-18 | 2003-03-27 | Onconova Therapeutics, Inc. | Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles |
US20030236308A1 (en) * | 2001-09-18 | 2003-12-25 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain |
CA2460939C (en) * | 2001-09-19 | 2008-07-29 | Pharmacia Corporation | Substituted pyrazolyl compounds for the treatment of inflammation |
CA2462297C (en) * | 2001-10-02 | 2009-04-07 | Pharmacia Corporation | Method for preparing benzenesulfonyl compounds |
AR037097A1 (es) | 2001-10-05 | 2004-10-20 | Novartis Ag | Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
JP2005510479A (ja) * | 2001-10-12 | 2005-04-21 | オンコノバ・セラピューティックス・インコーポレーテッド | 置換イソオキサゾールおよび置換2−イソオキサゾリンを調製する方法 |
US20030162824A1 (en) * | 2001-11-12 | 2003-08-28 | Krul Elaine S. | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor |
JP2005509002A (ja) * | 2001-11-13 | 2005-04-07 | ファルマシア コーポレイション | スルホンアミドプロドラックの経口剤形 |
DE60231439D1 (de) | 2001-12-06 | 2009-04-16 | Merck & Co Inc | Mitotische kinesinhemmer |
AU2002353147A1 (en) * | 2001-12-13 | 2003-06-30 | Abbott Laboratories | 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer |
US20040126438A1 (en) * | 2001-12-13 | 2004-07-01 | Obukowicz Mark G. | Selective cox-2 inhibition from plant extracts |
US20040062823A1 (en) * | 2001-12-13 | 2004-04-01 | Obukowicz Mark G. | Selective cox-2 inhibition from non-edible plant extracts |
EP1463500A1 (en) * | 2002-01-10 | 2004-10-06 | PHARMACIA & UPJOHN COMPANY | Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections |
US20030220374A1 (en) * | 2002-01-14 | 2003-11-27 | Pharmacia Corporation | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors |
US20030212138A1 (en) * | 2002-01-14 | 2003-11-13 | Pharmacia Corporation | Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
TW200403072A (en) * | 2002-01-23 | 2004-03-01 | Upjohn Co | Combination therapy for the treatment of bacterial infections |
US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US20100311701A1 (en) * | 2002-02-15 | 2010-12-09 | Transform Pharmaceuticals, Inc | Pharmaceutical Co-Crystal Compositions |
US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
EP1915992A1 (en) | 2002-02-19 | 2008-04-30 | Pharmacia Corporation | Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence |
EP1494998A2 (en) | 2002-03-01 | 2005-01-12 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
PL372880A1 (en) * | 2002-03-15 | 2005-08-08 | Pharmacia Corporation | Crystalline parecoxib sodium |
US8481772B2 (en) | 2002-04-01 | 2013-07-09 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid derivatives |
US7902257B2 (en) * | 2002-04-01 | 2011-03-08 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid |
JP2005522477A (ja) | 2002-04-08 | 2005-07-28 | グラクソ グループ リミテッド | (2−((2−アルコキシ)−フェニル)−シクロペント−1−エニル)芳香族炭素環式および複素環式酸および誘導体 |
JP2005532293A (ja) * | 2002-04-18 | 2005-10-27 | ファルマシア・コーポレーション | シクロオキシゲナーゼ−2(cox2)阻害剤を用いたパーキンソン病の治療のための単剤療法 |
WO2003088958A2 (en) * | 2002-04-18 | 2003-10-30 | Pharmacia Corporation | Combinations of cox-2 inhibitors and other agents for the treatment of parkinson’s disease |
WO2003095623A2 (en) * | 2002-05-10 | 2003-11-20 | The Trustees Of Columbia University In The City Of New York | Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof |
CA2489984A1 (en) * | 2002-06-21 | 2003-12-31 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
MXPA05000011A (es) * | 2002-06-26 | 2005-04-08 | Pharmacia Corp | Formulacion parenteral liquida estable de parecoxib. |
AU2003247622A1 (en) | 2002-06-27 | 2004-01-19 | Nitromed, Inc. | Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
JP2005535642A (ja) | 2002-06-28 | 2005-11-24 | ニトロメッド インコーポレーティッド | オキシムおよび/またはヒドラゾンを含有するニトロソ化および/またはニトロシル化シクロオキシゲナーゼ−2選択的阻害剤、組成物、および使用方法 |
BR0312402A (pt) * | 2002-07-02 | 2005-04-26 | Pharmacia Corp | Utilização de inibidores seletivos de ciclooxigenase-2 e agentes trombolìticos para o tratamento ou prevenção de um episódio vaso-oclusivo |
US7585856B2 (en) * | 2002-08-12 | 2009-09-08 | The Brigham And Women's Hospital, Inc. | Resolvins: Biotemplates for novel therapeutic interventions |
US7759395B2 (en) * | 2002-08-12 | 2010-07-20 | The Brigham And Women's Hospital, Inc. | Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma |
UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
AU2003267231A1 (en) * | 2002-09-20 | 2004-04-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
KR100484525B1 (ko) * | 2002-10-15 | 2005-04-20 | 씨제이 주식회사 | 이소티아졸 유도체, 그 제조방법 및 약제학적 조성물 |
US20040082543A1 (en) * | 2002-10-29 | 2004-04-29 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain |
GB0225548D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Compounds |
US20040092566A1 (en) * | 2002-11-12 | 2004-05-13 | Graneto Matthew J. | Celecoxib prodrug |
US20040147581A1 (en) * | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
US20050020658A1 (en) * | 2002-11-21 | 2005-01-27 | Katsuyuki Inoo | Selective cyclooxygenase-2 inhibitor patch |
US20040127531A1 (en) * | 2002-11-21 | 2004-07-01 | Lu Guang Wei | Adhesive coated sheet for dermal delivery of a selective cyclooxygenase-2 inhibitor |
US20040126415A1 (en) * | 2002-11-21 | 2004-07-01 | Lu Guang Wei | Dermal delivery of a water-soluble selective cyclooxygenase-2 inhibitor |
WO2004054560A1 (en) | 2002-12-13 | 2004-07-01 | Warner-Lambert Company Llc | Alpha-2-delta ligand to treat lower urinary tract symptoms |
US20040204411A1 (en) * | 2002-12-17 | 2004-10-14 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
US20040235925A1 (en) * | 2002-12-17 | 2004-11-25 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
US20080153894A1 (en) * | 2002-12-19 | 2008-06-26 | Pharmacia Corporation | Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis |
CN1726018A (zh) * | 2002-12-19 | 2006-01-25 | 法玛西雅公司 | 使用环加氧酶-2选择性抑制剂或环加氧酶-2抑制剂联合抗病毒剂治疗疱疹病毒感染的方法和组合物 |
WO2004058354A1 (en) * | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event |
ES2215474B1 (es) | 2002-12-24 | 2005-12-16 | J. URIACH & CIA S.A. | Nuevos derivados de fosforamida. |
ATE546134T1 (de) | 2002-12-26 | 2012-03-15 | Pozen Inc | Mehrschichtige dosierformen enthaltend naproxen und triptane |
WO2004060367A1 (en) * | 2002-12-30 | 2004-07-22 | Fujisawa Pharmaceutical Co., Ltd. | Imidazole and triazole derivatives useful as selective cox-1 inhibitors |
US8183290B2 (en) * | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
US20050026902A1 (en) * | 2003-01-31 | 2005-02-03 | Timothy Maziasz | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents |
US20040176378A1 (en) * | 2003-02-12 | 2004-09-09 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and an amphetamine for the treatment of reduced blood flow to the central nervous system |
WO2004078143A2 (en) * | 2003-03-05 | 2004-09-16 | The Brigham And Women's Hospital Inc. | Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs |
US20050004098A1 (en) * | 2003-03-20 | 2005-01-06 | Britten Nancy Jean | Dispersible formulation of an anti-inflammatory agent |
ATE337793T1 (de) * | 2003-03-20 | 2006-09-15 | Pharmacia Corp | Dispergierbare pharmazeutische zusammensetzung eines entzündungshemmers |
US20050009931A1 (en) * | 2003-03-20 | 2005-01-13 | Britten Nancy Jean | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
US20040214753A1 (en) * | 2003-03-20 | 2004-10-28 | Britten Nancy Jean | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
US20040214861A1 (en) * | 2003-03-28 | 2004-10-28 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine |
US20040220155A1 (en) * | 2003-03-28 | 2004-11-04 | Pharmacia Corporation | Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith |
WO2004087682A1 (en) * | 2003-04-04 | 2004-10-14 | Hetero Drugs Limited | Novel crystalline forms of parecoxib sodium |
MXPA05010937A (es) * | 2003-04-14 | 2005-11-25 | Inst For Pharm Discovery Inc | Derivados de fenilalanina n-(1,3-tiazol-2-il)amino)carbonil)fenil)sulfonil) y compuestos relacionados para el tratamiento de diabetes. |
WO2004093895A1 (en) * | 2003-04-22 | 2004-11-04 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders |
US20050009733A1 (en) * | 2003-04-22 | 2005-01-13 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage |
US20040224940A1 (en) * | 2003-04-22 | 2004-11-11 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of central nervous system damage |
WO2004093813A2 (en) * | 2003-04-22 | 2004-11-04 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders |
WO2004093814A2 (en) * | 2003-04-22 | 2004-11-04 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a sodium channel blocker |
WO2004093816A2 (en) * | 2003-04-22 | 2004-11-04 | Pharmacia Corporation | Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent |
CN1812977A (zh) | 2003-04-30 | 2006-08-02 | 药物研发有限责任公司 | 取代羧酸 |
US20040220167A1 (en) * | 2003-05-02 | 2004-11-04 | Nasrollah Samiy | Methods of treating neuralgic pain |
ATE342722T1 (de) | 2003-05-07 | 2006-11-15 | Osteologix As | Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen |
US20050107387A1 (en) * | 2003-05-13 | 2005-05-19 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders |
JP2006528245A (ja) * | 2003-05-14 | 2006-12-14 | ファルマシア コーポレイション | 中枢神経系への減少した血流又は外傷の治療のためのフェニル酢酸シクロオキシゲナーゼ−2選択的阻害剤及びコリン作動性剤の組成物 |
CA2525571A1 (en) * | 2003-05-14 | 2004-12-02 | Pharmacia Corporation | Compositions of a benzenesulfonamide or methylsulfonylbenzene cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to thecentral nervous system |
US20050159419A1 (en) * | 2003-05-14 | 2005-07-21 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage |
US20050026919A1 (en) * | 2003-05-14 | 2005-02-03 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system |
US20050113376A1 (en) * | 2003-05-27 | 2005-05-26 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor, a xanthine compound and an alcohol for the treatment of ischemic mediated central nervous system disorders or injury |
US20060160776A1 (en) * | 2003-05-28 | 2006-07-20 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage |
EA009646B1 (ru) | 2003-05-30 | 2008-02-28 | Рэнбакси Лабораториз Лтд. | Замещённые производные пиррола и их применение в качестве ингибиторов hmg-coa |
WO2005016243A2 (en) * | 2003-06-09 | 2005-02-24 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders |
WO2005000297A1 (en) * | 2003-06-24 | 2005-01-06 | Pharmacia Corporation | Treatment of migraine accompanied by nausea |
WO2005007156A1 (en) * | 2003-07-10 | 2005-01-27 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin ii receptor antagonist for the treatment of central nervous system damage |
US20050101597A1 (en) * | 2003-07-10 | 2005-05-12 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage |
WO2005018541A2 (en) * | 2003-07-11 | 2005-03-03 | Pharmacia Corporation | Cox-2 inhibitor and serotonin modulator for treating cns damage |
WO2005016249A2 (en) * | 2003-07-11 | 2005-02-24 | Pharmacia Corporation | Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ace inhibitor for the treatment of central nervous system damage |
WO2005009342A2 (en) * | 2003-07-16 | 2005-02-03 | Pharmacia Corporation | Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith |
US20050075341A1 (en) * | 2003-07-17 | 2005-04-07 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury |
WO2005012268A1 (ja) * | 2003-07-30 | 2005-02-10 | Shionogi & Co., Ltd. | イソオキサゾール環を有するスルホンアミド誘導体 |
CA2536173A1 (en) * | 2003-08-20 | 2005-03-03 | Nitromed, Inc. | Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use |
US20050119262A1 (en) * | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
WO2005018563A2 (en) * | 2003-08-22 | 2005-03-03 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury |
US20050107350A1 (en) * | 2003-08-22 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith |
EP1660079A2 (en) * | 2003-08-22 | 2006-05-31 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin modulating agent for the treatment of neoplasia |
WO2005018564A2 (en) * | 2003-08-22 | 2005-03-03 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage |
WO2005020910A2 (en) * | 2003-08-27 | 2005-03-10 | Pharmacia Corporation | Cyclooxygenase-2 selective inhibitor and corticotropin releasing factor antagonist compositions for treating ischemic mediated cns disorders or injuries |
CA2536967A1 (en) * | 2003-08-28 | 2005-03-17 | Nitromed, Inc. | Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use |
US20050187278A1 (en) * | 2003-08-28 | 2005-08-25 | Pharmacia Corporation | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors |
US20050113409A1 (en) * | 2003-09-03 | 2005-05-26 | Pharmacia Corporation | Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith |
JP2007511468A (ja) * | 2003-10-03 | 2007-05-10 | ファルマシア コーポレイション | 虚血仲介中枢神経系障害又は損傷の治療のための低体温状態下で投与されるシクロオキシゲナーゼ−2選択的阻害剤の組成物 |
WO2005046615A2 (en) * | 2003-11-12 | 2005-05-26 | Pharmacia & Upjohn Company Llc | Compositions for treatment of central nervous system mediated disorders |
EP1708700A1 (en) * | 2003-12-24 | 2006-10-11 | Pharmacia Corporation | Metal salts of parecoxib as prodrugs of the cox-2 inhibitor valdecoxib for the treatment of inflammation, pain and/or fever |
US7449462B2 (en) | 2004-01-22 | 2008-11-11 | Pfizer, Inc. | Triazole derivatives which inhibit vasopressin antagonistic activity |
WO2005105025A1 (en) * | 2004-04-14 | 2005-11-10 | Boston University | Methods and compositions for preventing or treating periodontal diseases |
EP1742932A1 (en) * | 2004-04-28 | 2007-01-17 | Pfizer Limited | 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor |
MXPA06015275A (es) | 2004-07-01 | 2007-03-15 | Merck & Co Inc | Inhibidores de quinasa mitotica. |
ES2257929B1 (es) * | 2004-07-16 | 2007-05-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos. |
RU2007101510A (ru) * | 2004-07-22 | 2008-08-27 | Фармаци Корпорейшн (US) | Композиции для лечения воспаления и боли с использованием комбинации селективного ингибитора сох-2 и антагониста рецептора ltb4 |
US8067464B2 (en) | 2004-10-04 | 2011-11-29 | Nitromed, Inc. | Compositions and methods using apocynin compounds and nitric oxide donors |
US20080300292A1 (en) * | 2004-11-08 | 2008-12-04 | Nitromed, Inc | Nitrosated and Nitrosylated Compounds, Compositions and Methods for the Treatment of Ophthalmic Disorders |
MX2007007830A (es) | 2004-12-23 | 2007-07-25 | Glaxo Group Ltd | Compuestos de piridina para el tratamiento de enfermedades mediadas por prostaglandina. |
EP1846380A4 (en) * | 2005-01-21 | 2010-02-17 | Nicox Sa | HETEROCYCLIC NITROGEN MONOXIDE DONOR COMPOSITIONS CONTAINING CARDIOVASCULAR COMPOUNDS, AND METHODS OF USING THE SAME |
JP2008530226A (ja) * | 2005-02-16 | 2008-08-07 | ニトロメッド インコーポレーティッド | 抗微生物化合物の有機酸化窒素供与体塩、組成物、および使用法 |
US7521435B2 (en) * | 2005-02-18 | 2009-04-21 | Pharma Diagnostics, N.V. | Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same |
CA2597463A1 (en) * | 2005-02-28 | 2006-09-08 | Nitromed, Inc. | Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use |
EP2444419A1 (en) | 2005-04-26 | 2012-04-25 | Pfizer Inc. | P-Cadherin antibodies |
CA2607913C (en) * | 2005-05-05 | 2014-03-18 | Cook Biotech Incorporated | Implantable materials and methods for inhibiting tissue adhesion formation |
WO2006123182A2 (en) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Cyclohexyl sulphones for treatment of cancer |
JP2008540633A (ja) * | 2005-05-18 | 2008-11-20 | ファイザー・リミテッド | バソプレッシン拮抗薬としての1,2,4−トリアゾール誘導体 |
US20090048219A1 (en) * | 2005-05-23 | 2009-02-19 | Nitromed Inc. | Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use |
HUP0500730A2 (en) * | 2005-07-29 | 2007-02-28 | Richter Gedeon Vegyuszeti Gyar | 1,2-diaryl-heterocyclic compounds, their preparation, pharmaceutical compositions comprising thereof and their use |
WO2007016677A2 (en) | 2005-08-02 | 2007-02-08 | Nitromed, Inc. | Nitric oxide enhancing antimicrobial compounds, compositions and methods of use |
TW200804345A (en) * | 2005-08-30 | 2008-01-16 | Novartis Ag | Substituted benzimidazoles and methods of preparation |
PE20080035A1 (es) | 2005-09-07 | 2008-01-30 | Amgen Fremont Inc | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina |
WO2007041440A2 (en) | 2005-10-03 | 2007-04-12 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers |
CA2624933A1 (en) * | 2005-10-04 | 2007-04-12 | Nitromed, Inc. | Methods for treating respiratory disorders |
AU2006313430B2 (en) | 2005-11-08 | 2012-09-06 | Ranbaxy Laboratories Limited | Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
US7838023B2 (en) * | 2005-11-16 | 2010-11-23 | Nitromed, Inc. | Furoxan compounds, compositions and methods of use |
JP2009515991A (ja) | 2005-11-18 | 2009-04-16 | トラスティーズ オブ ボストン ユニバーシティ | レゾルビンを使用する骨喪失の処置および防止 |
EP1968584A2 (en) * | 2005-12-20 | 2008-09-17 | Nitromed, Inc. | Nitric oxide enhancing glutamic acid compounds, compositions and methods of use |
NL2000351C2 (nl) | 2005-12-22 | 2007-09-11 | Pfizer Prod Inc | Estrogeen-modulatoren. |
EP1971340A2 (en) * | 2005-12-22 | 2008-09-24 | Nitromed, Inc. | Nitric oxide enhancing pyruvate compounds, compositions and methods of use |
US20090062302A1 (en) | 2006-01-24 | 2009-03-05 | Buser-Doepner Carolyn A | Jak2 Tyrosine Kinase Inhibition |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
EP2007705A4 (en) | 2006-03-29 | 2011-09-07 | Nicox Sa | NITROGEN MONOXIDE REINFORCING PROSTAGLANDIN COMPOUNDS, COMPOSITION AND APPLICATION PROCESS |
PL2010528T3 (pl) | 2006-04-19 | 2018-03-30 | Novartis Ag | 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r |
CA2651732C (en) | 2006-05-18 | 2014-10-14 | Mannkind Corporation | Intracellular kinase inhibitors |
WO2008033931A1 (en) * | 2006-09-13 | 2008-03-20 | The Institutes For Pharmaceutical Discovery, Llc | Para-xylylene carboxylic acids and isothiazolones useful as protein tyrosine phosphatases (ptps) in particular ptp-ib |
EP2946778A1 (en) | 2006-09-22 | 2015-11-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
MX2009006575A (es) | 2006-12-22 | 2009-07-02 | Recordati Ireland Ltd | Terapia de combinacion de trastornos del tracto urinario inferior con ligandos a2d y farmacos anti-inflamatorios no esteroidales (nsaids). |
EP2109608B1 (en) | 2007-01-10 | 2011-03-23 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
KR100843351B1 (ko) * | 2007-01-30 | 2008-07-03 | 한국과학기술연구원 | 중추신경계 질환 치료제로 유효한n-벤질-n-(2-디메틸아미노-에틸)-벤젠술폰아미드 화합물 |
EA019951B1 (ru) | 2007-03-01 | 2014-07-30 | Новартис Аг | Ингибиторы киназы pim и способы их применения |
GB0704407D0 (en) | 2007-03-07 | 2007-04-18 | Glaxo Group Ltd | Compounds |
KR20100017866A (ko) | 2007-05-21 | 2010-02-16 | 노파르티스 아게 | Csf-1r 억제제, 조성물 및 사용 방법 |
EP3103791B1 (en) | 2007-06-27 | 2018-01-31 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
CN101801188A (zh) | 2007-07-12 | 2010-08-11 | 特拉加拉医药品公司 | 治疗癌症、肿瘤和肿瘤相关性疾病的方法和组合物 |
US7943658B2 (en) | 2007-07-23 | 2011-05-17 | Bristol-Myers Squibb Company | Indole indane amide compounds useful as CB2 agonists and method |
CN101854933A (zh) | 2007-09-10 | 2010-10-06 | 钙医学公司 | 调节细胞内钙的化合物 |
WO2009111354A2 (en) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
EP2321303B1 (en) | 2008-08-27 | 2019-11-27 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
EP2177215A1 (en) | 2008-10-17 | 2010-04-21 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of tramadol and NSAIDs |
JP5212177B2 (ja) * | 2009-02-27 | 2013-06-19 | 東レ株式会社 | γ−ケトアセタール化合物及びピロール誘導体の製造方法 |
GB0903493D0 (en) | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
KR101069175B1 (ko) | 2009-04-19 | 2011-09-30 | 중앙대학교 산학협력단 | 신규 아미노설포닐아릴이소옥사졸계 화합물 및 이를 포함하는 다약제내성 억제용 약제학적 조성물 |
WO2011012622A1 (en) | 2009-07-30 | 2011-02-03 | Glaxo Group Limited | Benzoxazinone derivatives for the treatment of glytl mediated disorders |
WO2011023753A1 (en) | 2009-08-27 | 2011-03-03 | Glaxo Group Limited | Benzoxazine derivatives as glycine transport inhibitors |
CN104945382B (zh) | 2009-10-14 | 2020-02-07 | 默沙东公司 | 提高p53活性的取代的哌啶和其用途 |
GB201000685D0 (en) | 2010-01-15 | 2010-03-03 | Glaxo Group Ltd | Novel compounds |
CN101805290A (zh) * | 2010-04-01 | 2010-08-18 | 中国人民解放军第四军医大学 | 氨基磺酰吡唑类化合物及其用途 |
ES2591004T3 (es) | 2010-04-27 | 2016-11-24 | Calcimedica, Inc. | Compuestos moduladores del calcio intracelular |
AU2011248579A1 (en) | 2010-04-27 | 2012-11-29 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
GB201007791D0 (en) | 2010-05-10 | 2010-06-23 | Glaxo Group Ltd | Novel compounds |
GB201007789D0 (en) | 2010-05-10 | 2010-06-23 | Glaxo Group Ltd | Novel Compound |
US20130072519A1 (en) | 2010-05-21 | 2013-03-21 | Edward Lee Conn | 2-phenyl benzoylamides |
US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
WO2012004604A1 (en) | 2010-07-09 | 2012-01-12 | Convergence Pharmaceuticals Limited | Tetrazole compounds as calcium channel blockers |
JP6043285B2 (ja) | 2010-08-02 | 2016-12-14 | サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. | 低分子干渉核酸(siNA)を用いたカテニン(カドヘリン結合型タンパク質)β1(CTNNB1)遺伝子発現のRNA干渉媒介性阻害 |
CN108676800B (zh) | 2010-08-17 | 2022-11-11 | 瑟纳治疗公司 | 使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制 |
AU2011291614B2 (en) * | 2010-08-20 | 2016-05-26 | Allergan, Inc. | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
CN103180316A (zh) | 2010-08-27 | 2013-06-26 | 钙医学公司 | 调节细胞内钙的化合物 |
EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
ES2663009T3 (es) | 2010-10-29 | 2018-04-10 | Sirna Therapeutics, Inc. | Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic) |
EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
JP6058556B2 (ja) | 2011-01-19 | 2017-01-11 | クオンベルゲンセ プハルマセウトイカルス リミテッド | CaV2.2カルシウムチャンネルブロッカーとしてのピペラジン誘導体 |
EP2680874A2 (en) | 2011-03-04 | 2014-01-08 | Pfizer Inc | Edn3-like peptides and uses thereof |
CN103732592A (zh) | 2011-04-21 | 2014-04-16 | 默沙东公司 | 胰岛素样生长因子-1受体抑制剂 |
WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
US9221809B2 (en) | 2011-10-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
US9562015B2 (en) | 2011-11-17 | 2017-02-07 | The Regents Of The University Of Colorado, A Body | Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations |
GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
EP3358013B1 (en) | 2012-05-02 | 2020-06-24 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
CN105050598B (zh) | 2012-09-28 | 2018-04-27 | 默沙东公司 | 作为erk抑制剂的新型化合物 |
US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
CA2892361A1 (en) | 2012-11-28 | 2014-06-05 | Merck Sharp & Dohme Corp. | Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels |
AU2013361694B2 (en) | 2012-12-20 | 2017-10-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
JP6480909B2 (ja) * | 2013-03-15 | 2019-03-13 | ユニバーシティー オブ サウザン カリフォルニア | アンギオテンシン関連疾患の処置のための方法、化合物および組成物 |
US20160166576A1 (en) | 2013-07-11 | 2016-06-16 | Merck Sharp & Dohme Corp. | Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4) |
EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
CN104418818B (zh) * | 2013-09-04 | 2017-01-11 | 天津汉瑞药业有限公司 | 帕瑞昔布钠无水化合物 |
US9611263B2 (en) | 2013-10-08 | 2017-04-04 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
CN105085425B (zh) * | 2014-05-23 | 2018-01-30 | 昆药集团股份有限公司 | 一种制备帕瑞昔布的方法 |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
GB201417497D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
GB201417499D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
GB201417500D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
CN104557754A (zh) * | 2015-01-04 | 2015-04-29 | 成都克莱蒙医药科技有限公司 | 一种帕瑞昔布钠杂质的合成方法 |
EP3267996B1 (en) | 2015-03-12 | 2020-11-11 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of irak4 activity |
WO2016144849A1 (en) | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Thienopyrazine inhibitors of irak4 activity |
WO2016144844A1 (en) | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Carboxamide inhibitors of irak4 activity |
EP3328827B1 (en) * | 2015-07-31 | 2023-07-05 | The Johns Hopkins University | Prodrugs of glutamine analogs |
US9598361B1 (en) * | 2016-04-12 | 2017-03-21 | King Saud University | Amino substituted acetamide derivative |
EP3525785A4 (en) | 2016-10-12 | 2020-03-25 | Merck Sharp & Dohme Corp. | KDM5 INHIBITORS |
WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
CN108299331A (zh) * | 2018-03-02 | 2018-07-20 | 成都新恒创药业有限公司 | 一种帕瑞昔布钠光降解杂质及其制备、检测方法和应用 |
CN108164521B (zh) * | 2018-03-02 | 2020-11-13 | 成都新恒创药业有限公司 | 一种帕瑞昔布钠降解杂质及其制备、检测方法和应用 |
US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
CN110305071A (zh) * | 2019-07-23 | 2019-10-08 | 成都通德药业有限公司 | 一种帕瑞昔布钠中间体帕瑞昔布的合成方法 |
CN115087638B (zh) | 2019-12-17 | 2023-11-24 | 默沙东公司 | Prmt5抑制剂 |
WO2022195579A1 (en) | 2021-03-15 | 2022-09-22 | Saul Yedgar | Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases |
CN115784991A (zh) * | 2022-11-22 | 2023-03-14 | 合肥医工医药股份有限公司 | N-(苯磺酰基)酰胺衍生物及其制备方法和用途 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US538738A (en) | 1895-05-07 | Measuring-faucet | ||
GB911204A (en) | 1960-07-28 | 1962-11-21 | Unilever Ltd | Bleaching compositions |
US4146721A (en) | 1969-09-12 | 1979-03-27 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyrazol-4-acetic acid compounds |
US3984431A (en) | 1972-03-15 | 1976-10-05 | Claude Gueremy | Derivatives of pyrazole-5-acetic acid |
DE3321082C2 (de) | 1982-06-10 | 1996-08-22 | Kao Corp | Bleich-Reinigungsmittel |
JPS59145300A (ja) | 1983-02-07 | 1984-08-20 | 日本パ−オキサイド株式会社 | 漂白洗剤 |
JPS6015500A (ja) | 1983-07-08 | 1985-01-26 | ライオン株式会社 | 高嵩密度洗剤組成物 |
JPS60118606A (ja) | 1983-11-28 | 1985-06-26 | Mitsubishi Gas Chem Co Inc | 安定化された過炭酸ナトリウム粒状物 |
US5051518A (en) | 1987-05-29 | 1991-09-24 | Ortho Pharmaceutical Corporation | Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides |
JP2590124B2 (ja) * | 1987-08-12 | 1997-03-12 | 国際試薬株式会社 | 水溶性テトラゾリウム化合物およびその化合物を用いる還元性物質の測定方法 |
JPS6445374U (xx) | 1987-09-10 | 1989-03-20 | ||
DE3903993A1 (de) * | 1989-02-10 | 1990-08-16 | Basf Ag | Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus |
JPH04277724A (ja) * | 1991-03-06 | 1992-10-02 | Sumitomo Electric Ind Ltd | 有機非線形光学材料 |
GB9113628D0 (en) * | 1991-06-25 | 1991-08-14 | Ici Plc | Heterocyclic derivatives |
US5219856A (en) * | 1992-04-06 | 1993-06-15 | E. I. Du Pont De Nemours And Company | Angiotensin-II receptor blocking, heterocycle substituted imidazoles |
US5334991A (en) | 1992-05-15 | 1994-08-02 | Reflection Technology | Dual image head-mounted display |
JPH05323522A (ja) * | 1992-05-20 | 1993-12-07 | Fuji Photo Film Co Ltd | 黒白ハロゲン化銀写真感光材料の処理方法 |
US5604260A (en) * | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
AU6027694A (en) * | 1993-01-15 | 1994-08-15 | G.D. Searle & Co. | Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents |
US5409944A (en) * | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
CA2161789A1 (en) * | 1993-05-13 | 1994-11-24 | Jacques Yves Gauthier | 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase |
US5380738A (en) * | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5344991A (en) * | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
US5434178A (en) | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
PL180717B1 (pl) * | 1993-11-30 | 2001-03-30 | Searle & Co | N o w e 1 -[4-(aminosulfonylo)fenylo]pirazolilobenzenosulfonamidy do leczenia stanów zapalnych PL PL PL PL PL PL PL |
US5401765A (en) | 1993-11-30 | 1995-03-28 | G. D. Searle | 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders |
US5393790A (en) * | 1994-02-10 | 1995-02-28 | G.D. Searle & Co. | Substituted spiro compounds for the treatment of inflammation |
DE69509223T2 (de) * | 1994-02-10 | 1999-09-16 | G.D. Searle & Co., Chicago | Substituierte spiroverbindungen zur behandlung von entzündungen |
US5486534A (en) | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
US5556019A (en) * | 1994-07-25 | 1996-09-17 | Sealed Air Corporation | Bag separator and dispenser |
US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
JP2636819B2 (ja) * | 1994-12-20 | 1997-07-30 | 日本たばこ産業株式会社 | オキサゾール系複素環式芳香族化合物 |
JP3181190B2 (ja) * | 1994-12-20 | 2001-07-03 | 日本たばこ産業株式会社 | オキサゾール誘導体 |
US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
US5908858A (en) * | 1996-04-05 | 1999-06-01 | Sankyo Company, Limited | 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses |
WO1997038986A1 (en) * | 1996-04-12 | 1997-10-23 | G.D. Searle & Co. | Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors |
JPH1045374A (ja) | 1996-08-01 | 1998-02-17 | Nittetsu Mining Co Ltd | ドラム缶吊り上げ装置 |
US20030105144A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
-
1997
- 1997-04-11 WO PCT/US1997/005497 patent/WO1997038986A1/en active IP Right Grant
- 1997-04-11 AT AT97921092T patent/ATE233743T1/de active
- 1997-04-11 DE DE69719496T patent/DE69719496T2/de not_active Expired - Lifetime
- 1997-04-11 PT PT02025005T patent/PT1288206E/pt unknown
- 1997-04-11 SI SI9720035A patent/SI9720035B/sl active Search and Examination
- 1997-04-11 AT AT02025005T patent/ATE408607T1/de active
- 1997-04-11 DE DE69739003T patent/DE69739003D1/de not_active Expired - Lifetime
- 1997-04-11 CZ CZ0271098A patent/CZ297430B6/cs not_active IP Right Cessation
- 1997-04-11 KR KR10-1998-0708126A patent/KR100387658B1/ko not_active IP Right Cessation
- 1997-04-11 AP APAP/P/1998/001355A patent/AP1009A/en active
- 1997-04-11 EA EA199800919A patent/EA003319B1/ru not_active IP Right Cessation
- 1997-04-11 SI SI9720101A patent/SI22713B/sl active Search and Examination
- 1997-04-11 TR TR1998/02049T patent/TR199802049T2/xx unknown
- 1997-04-11 DK DK02025005T patent/DK1288206T3/da active
- 1997-04-11 IL IL12584997A patent/IL125849A/xx not_active IP Right Cessation
- 1997-04-11 IL IL153738A patent/IL153738A/en not_active IP Right Cessation
- 1997-04-11 CN CN97193747A patent/CN1098256C/zh not_active Expired - Lifetime
- 1997-04-11 PL PL97329276A patent/PL195955B1/pl unknown
- 1997-04-11 NZ NZ331542A patent/NZ331542A/xx not_active IP Right Cessation
- 1997-04-11 DK DK97921092T patent/DK0892791T3/da active
- 1997-04-11 PT PT97921092T patent/PT892791E/pt unknown
- 1997-04-11 RO RO98-01469A patent/RO121338B1/ro unknown
- 1997-04-11 BR BR9708574A patent/BR9708574A/pt active Search and Examination
- 1997-04-11 ES ES97921092T patent/ES2194195T3/es not_active Expired - Lifetime
- 1997-04-11 ES ES02025005T patent/ES2311571T3/es not_active Expired - Lifetime
- 1997-04-11 EE EE9800351A patent/EE03685B1/xx active Protection Beyond IP Right Term
- 1997-04-11 CA CA002249009A patent/CA2249009C/en not_active Expired - Lifetime
- 1997-04-11 ME MEP-1998-443A patent/ME00768B/me unknown
- 1997-04-11 JP JP53713997A patent/JP3382624B2/ja not_active Expired - Lifetime
- 1997-04-11 SK SK1242-98A patent/SK285353B6/sk not_active IP Right Cessation
- 1997-04-11 HU HU9901807A patent/HU225473B1/hu unknown
- 1997-04-11 AU AU27227/97A patent/AU734275C/en not_active Ceased
- 1997-04-11 EP EP97921092A patent/EP0892791B1/en not_active Expired - Lifetime
- 1997-04-11 EP EP02025005A patent/EP1288206B1/en not_active Expired - Lifetime
- 1997-04-11 GE GEAP19974523A patent/GEP20032998B/en unknown
- 1997-04-14 ZA ZA9703146A patent/ZA973146B/xx unknown
- 1997-05-02 BR BR1100403-7A patent/BR1100403A/pt active IP Right Grant
- 1997-05-26 TW TW086107093A patent/TW585857B/zh not_active IP Right Cessation
- 1997-10-09 RS YUP-443/98A patent/RS50019B/sr unknown
- 1997-11-04 UA UA98115994A patent/UA47475C2/uk unknown
-
1998
- 1998-01-12 US US09/005,610 patent/US5932598A/en not_active Expired - Lifetime
- 1998-10-09 LT LT98-142A patent/LT4586B/lt not_active IP Right Cessation
- 1998-10-09 IS IS4863A patent/IS2156B/is unknown
- 1998-10-09 NO NO19984727A patent/NO314184B1/no not_active IP Right Cessation
- 1998-10-12 LV LVP-98-215A patent/LV12239B/en unknown
- 1998-10-12 OA OA9800193A patent/OA11015A/en unknown
- 1998-10-12 CU CU147A patent/CU23116A3/es unknown
- 1998-11-12 BG BG102916A patent/BG64531B1/bg unknown
- 1998-11-12 BG BG109057A patent/BG109057A/bg unknown
-
1999
- 1999-11-01 HK HK99104900A patent/HK1019741A1/xx not_active IP Right Cessation
-
2000
- 2000-09-14 US US09/661,859 patent/US6436967B1/en not_active Expired - Lifetime
-
2002
- 2002-06-24 US US10/178,697 patent/US6815460B2/en not_active Expired - Fee Related
- 2002-09-04 JP JP2002258955A patent/JP4049307B2/ja not_active Expired - Lifetime
- 2002-12-30 IL IL15373802A patent/IL153738A0/xx active IP Right Grant
-
2004
- 2004-06-02 IS IS7292A patent/IS7292A/is unknown
- 2004-09-13 US US10/939,852 patent/US7420061B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE9800351A (et) | Asendatud benseensulfoonamiidi derivaadid kui COX-2 inhibiitorite eelravimid | |
LV12232A (lv) | Zinami fosfinilatvasinajumi ka naaldazes inhibitori | |
EE9900506A (et) | Asendatud bensopüraani derivaadid põletiku raviks | |
PT944631E (pt) | Novos derivados substituidos de pirazole para tratamento de doencas cardiovasculares | |
EE200100086A (et) | Hüdroksüpipekolaadi hüdroksaamhappe derivaadid kui MMP inhibiitorid | |
DK1475377T3 (da) | Indol-derivater og deres anvendelse som inhibitorer for phosphodiesterase 4 | |
DK1001934T3 (da) | Indolforbindelser som COX-2-inhibitorer | |
NO992725D0 (no) | 6-Fenylpyridyl-2-amin-derivater anvendelige som NOS-inhibitorer | |
EE200000289A (et) | Asendatud 4-amino-tiasool-2-üüli ühendid kui tsükliinisõltuvusega kinaaside inhibiitorid | |
DE69716615D1 (de) | Heterozyklische metalloproteaseinhibitoren | |
PT927183E (pt) | Inibidores espirociclicos de metaloproteases | |
IS5772A (is) | Þalazín (phthalazine) afleiður af fosfódíesterasa4 lötum | |
NO995267L (no) | Leptin som en inhibitor av tumorcelleproliferering | |
EE9800335A (et) | Pürrolopürrolooni derivaadid kui neutrofiilelastaasi inhibiitorid | |
PT934280E (pt) | Derivados 2-cianoiminoimidazolo inibidores da pde iv | |
DE69805334D1 (de) | Derivate des vitamin e | |
EE03745B1 (et) | Asendatud 4-bifenüül-4-hüdroksübutaanhappe derivaadid metalloproteaasimaatriksi inhibiitoritena | |
NO20005301D0 (no) | Pyrrolidiner som inhibitorer av neuraminidaser | |
NO20001200D0 (no) | Pyrrolopyrrolonderivater som inhibitorer av neurofil elastase | |
EE200100017A (et) | N-tert-butüülhüdroksüülamiini uued soolad | |
EE9900585A (et) | 6-asauratsiili derivaadid IL-5 inhibiitoritena | |
BR9704770A (pt) | Derivados de 1-carba-(detia)-cefalosporina | |
UA25380A (uk) | Розчиhhик для розбавлеhhя hітроцелюлозhих лаків | |
BR1100811A (pt) | Derivados de 1-metil-carbapenema | |
EE200300194A (et) | Asendatud bensopüraani derivaatide kasutamine põletiku raviks |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB4A | Valid patent at the end of a year |
Effective date: 20021231 |
|
AA1Y | Spc filed |
Free format text: PRODUCT NAME: DYNASTAT; REG NO/DATE: 009371 21.08.2002 RA 009372 21.08.2002 RA 009373 21.08.2002RA 009374 21.08.2002 Spc suppl protection certif: C20030001 Filing date: 20030217 |
|
FG1Y | Spc granted |
Free format text: PRODUCT NAME: DYNASTAT; REG NO/DATE: 009371 21.08.2002 RA 009372 21.08.2002 RA 009373 21.08.2002RA 009374 21.08.2002 Spc suppl protection certif: C20030001 00003 Filing date: 20030217 Extension date: 20170816 |
|
HE1A | Change of address | ||
KB4A | Valid patent at the end of a year |
Effective date: 20031231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20041231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20051231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20061231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20071231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20091231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |